Collaborative pharmacy practice agreement - statewide drug therapy protocol for medication-assisted treatment for opioid use disorder - rules - definition

(1) As used in this section, "medication-assisted treatment" means a combination of medications and behavioral therapy, such as buprenorphine and all other medications and therapies approved by the federal food and drug administration, to treat opioid use disorder. (2) (a) Pursuant to section 12-280-603, the board, in conjunction with the Colorado medical board created in section 12-240-105 and the state board of nursing created in section 12-255-105, shall promulgate rules no later than May 1, 2025, developing a statewide drug therapy protocol for pharmacists to prescribe, dispense, and administer only federal drug enforcement administration schedule III, IV, and V FDA-approved products as medication-assisted treatment for opioid use disorder. (b) In developing the statewide drug therapy protocol, the applicable boards shall consider requirements for training, including a program accredited by the Accreditation Council for Pharmacy Education, or its successor entity; patient notice and consent; provider referral criteria; lab screening and testing; monitoring; patient privacy; and patient follow-up care and counseling. The rules developed pursuant to subsection (2)(a) of this section must specify that any collaborating entities utilizing the protocol are clearly identified. (3) This section does not require a statewide drug therapy protocol or collaborative pharmacy practice agreement before a pharmacist may prescribe, dispense, or administer only federal drug enforcement administration schedule III, IV, and V FDA-approved products as medication-assisted treatment, if the prescribing, dispensing, or administering medication-assisted treatment is otherwise authorized under law.